Pharma R&D
Pharma R&D
Pharma R&D
Pharma R&D
Innovation Milestones
First to identify novel Cancer Progression-Associated Signatures (CPAS) across a range of cancers.
First US & China patents granted in August 2020 (Methods for determining the cause of somatic mutagenesis).
Expanded IIF profiling methods in CPAS in additional cancers, analyzing 10,000+ patients and achieving high accuracy, sensitivity and specificity.
Completed 3 lung cancer validation studies, achieving a predictive accuracy of ~90% using whole exome data in determining non-responders to immunotherapy treatment.
Clinical validation studies of Lung Cancer Treatment Response to be analyzed and completed in 2024.
2020
2024
First to use deaminase-associated mutations for predicting patient response to immuno-oncology therapies.
Healthy Population Clinical Trial (Monash Clinical Trial Precinct).
Hepatitis B Stop Clinical Trial to identify patients who can safely stop long term antiviral treatment.
First to show that inherited human SNPs are likely caused by mutagenic deaminase activity.
First to use blood DNA to develop Innate Immune Fitness (IIF) scores for stratifying patients with diseases.
Proof of Concept to predict IO responders using >14 datasets across 5 therapies and cancers.
2016
2019
First to show that strand-biased mutation patterns seen in immune genes are the same as in many cancers.
First to show that AID/APOBEC and ADAR deaminase- associated mutations occur in protein reading– frame context.
Initiated basic research to identify deaminase signatures.
First patent application (Federal Government Innovation Support Grant).
First desktop tool built to automate genomic analysis.
First to identify novel Cancer-Progression Associated Signatures (CPAS) in ovarian cancer.